Literature DB >> 11045625

Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor.

A Velazquez-Campoy1, I Luque, M J Todd, M Milutinovich, Y Kiso, E Freire.   

Abstract

KNI-272 is a powerful HIV-1 protease inhibitor with a reported inhibition constant in the picomolar range. In this paper, a complete experimental dissection of the thermodynamic forces that define the binding affinity of this inhibitor to the wild-type and drug-resistant mutant V82F/184V is presented. Unlike other protease inhibitors, KNI-272 binds to the protease with a favorable binding enthalpy. The origin of the favorable binding enthalpy has been traced to the coupling of the binding reaction to the burial of six water molecules. These bound water molecules, previously identified by NMR studies, optimize the atomic packing at the inhibitor/protein interface enhancing van der Waals and other favorable interactions. These interactions offset the unfavorable enthalpy usually associated with the binding of hydrophobic molecules. The association constant to the drug resistant mutant is 100-500 times weaker. The decrease in binding affinity corresponds to an increase in the Gibbs energy of binding of 3-3.5 kcal/mol, which originates from less favorable enthalpy (1.7 kcal/mol more positive) and entropy changes. Calorimetric binding experiments performed as a function of pH and utilizing buffers with different ionization enthalpies have permitted the dissection of proton linkage effects. According to these experiments, the binding of the inhibitor is linked to the protonation/deprotonation of two groups. In the uncomplexed form these groups have pKs of 6.0 and 4.8, and become 6.6 and 2.9 in the complex. These groups have been identified as one of the aspartates in the catalytic aspartyl dyad in the protease and the isoquinoline nitrogen in the inhibitor molecule. The binding affinity is maximal between pH 5 and pH 6. At those pH values the affinity is close to 6 x 10(10) M(-1) (Kd = 16 pM). Global analysis of the data yield a buffer- and pH-independent binding enthalpy of -6.3 kcal/mol. Under conditions in which the exchange of protons is zero, the Gibbs energy of binding is -14.7 kcal/mol from which a binding entropy of 28 cal/K mol is obtained. Thus, the binding of KNI-272 is both enthalpically and entropically favorable. The structure-based thermodynamic analysis indicates that the allophenylnorstatine nucleus of KNI-272 provides an important scaffold for the design of inhibitors that are less susceptible to resistant mutations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045625      PMCID: PMC2144700          DOI: 10.1110/ps.9.9.1801

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  27 in total

1.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

Authors:  K Yoshimura; R Kato; K Yusa; M F Kavlick; V Maroun; A Nguyen; T Mimoto; T Ueno; M Shintani; J Falloon; H Masur; H Hayashi; J Erickson; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

Authors:  J Trylska; J Antosiewicz; M Geller; C N Hodge; R M Klabe; M S Head; M K Gilson
Journal:  Protein Sci       Date:  1999-01       Impact factor: 6.725

Review 3.  Thermodynamics of structural stability and cooperative folding behavior in proteins.

Authors:  K P Murphy; E Freire
Journal:  Adv Protein Chem       Date:  1992

Review 4.  Study of strong to ultratight protein interactions using differential scanning calorimetry.

Authors:  J F Brandts; L N Lin
Journal:  Biochemistry       Date:  1990-07-24       Impact factor: 3.162

5.  The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease.

Authors:  M J Todd; E Freire
Journal:  Proteins       Date:  1999-08-01

6.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

7.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Authors:  M Markowitz; H Mo; D J Kempf; D W Norbeck; T N Bhat; J W Erickson; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Estimation of changes in side chain configurational entropy in binding and folding: general methods and application to helix formation.

Authors:  K H Lee; D Xie; E Freire; L M Amzel
Journal:  Proteins       Date:  1994-09

9.  Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.

Authors:  T Mimoto; R Kato; H Takaku; S Nojima; K Terashima; S Misawa; T Fukazawa; T Ueno; H Sato; M Shintani; Y Kiso; H Hayashi
Journal:  J Med Chem       Date:  1999-05-20       Impact factor: 7.446

10.  HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity.

Authors:  A Velazquez-Campoy; M J Todd; E Freire
Journal:  Biochemistry       Date:  2000-03-07       Impact factor: 3.162

View more
  25 in total

1.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Adrian Velázquez-Campoy; Dong Xie; Ernesto Freire
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

Review 3.  Finding a better path to drug selectivity.

Authors:  Yuko Kawasaki; Ernesto Freire
Journal:  Drug Discov Today       Date:  2011-08-02       Impact factor: 7.851

4.  Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.

Authors:  Jay Chauhan; Shen-En Chen; Katherine J Fenstermacher; Aurash Naser-Tavakolian; Tali Reingewertz; Rosene Salmo; Christian Lee; Emori Williams; Mithun Raje; Eric Sundberg; Jeffrey J DeStefano; Ernesto Freire; Steven Fletcher
Journal:  Bioorg Med Chem       Date:  2015-09-07       Impact factor: 3.641

5.  Exact analysis of heterotropic interactions in proteins: Characterization of cooperative ligand binding by isothermal titration calorimetry.

Authors:  Adrian Velazquez-Campoy; Guillermina Goñi; Jose Ramon Peregrina; Milagros Medina
Journal:  Biophys J       Date:  2006-06-09       Impact factor: 4.033

6.  A fast and accurate computational approach to protein ionization.

Authors:  Velin Z Spassov; Lisa Yan
Journal:  Protein Sci       Date:  2008-08-19       Impact factor: 6.725

7.  How much binding affinity can be gained by filling a cavity?

Authors:  Yuko Kawasaki; Eduardo E Chufan; Virginie Lafont; Koushi Hidaka; Yoshiaki Kiso; L Mario Amzel; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2009-12-17       Impact factor: 2.817

8.  Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.

Authors:  Yongyuth Yuthavong; Bongkoch Tarnchompoo; Tirayut Vilaivan; Penchit Chitnumsub; Sumalee Kamchonwongpaisan; Susan A Charman; Danielle N McLennan; Karen L White; Livia Vivas; Emily Bongard; Chawanee Thongphanchang; Supannee Taweechai; Jarunee Vanichtanankul; Roonglawan Rattanajak; Uthai Arwon; Pascal Fantauzzi; Jirundon Yuvaniyama; William N Charman; David Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

9.  Enthalpy screen of drug candidates.

Authors:  Arne Schön; Ernesto Freire
Journal:  Anal Biochem       Date:  2016-08-25       Impact factor: 3.365

Review 10.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.